Vadodara, January 22nd, 2020
Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st December 2019.
Revenue for the quarter up 19% to Rs 1209 crores from Rs. 1018 crores
Net Profit for the quarter up 38% to Rs 234 crores from Rs 170 crores
Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “It was a good quarter for the company led by strong growth in the International Markets. We launched 7 products in the US market during the quarter.”
International formulations grew 48% to Rs 664 crores in the quarter.
US Generics grew 61% to Rs 515 crores in the quarter.
Ex-US Sales grew 15% to Rs 149 crores in the quarter.
8 ANDA approvals received during the quarter and total tally stand at 110.
6 ANDA filings during the quarter; Cumulative ANDA filings at 176
India Formulations Business
The India formulations business was Rs 368 crores for the quarter as against Rs 365 crores last year.
The API business grew 2% to Rs 553 crores as against Rs 540 crores .
2 DMF were filled in the quarter.